Aktuelle Diagnostik und Therapie von Gallengangs- und Gallenblasenkarzinomen

Zusammenfassung

Karzinome des Gallenwegsystems sind seltene Tumoren des Gastrointestinaltrakts mit in den letzten Jahren zunehmender Inzidenz. Sie werden unterteilt in intra- und extrahepatische Gallengangskarzinome (Klatskin-Tumor, mittleres und distales Gallengangskarzinom), Gallenblasenkarzinom und Papillenkarzinom. Die Umwandlung von normalem in malignes Gallengangsgewebe erfordert eine Reihe von aufeinander folgenden Genmutationen, ähnlich der Adenom-Dysplasie-Karzinom-Sequenz beim Kolonkarzinom. Der abdominelle Ultraschall, die nichtinvasive kombinierte Magnetresonanzcholangiographie/-tomographie (MRC/MRT) und fakultativ bei fraglicher Diagnose die endoskopische retrograde Cholangiographie (ERC) stellen in der Primärdiagnostik den Goldstandard dar. Beim Papillenkarzinom ist die Endosonographie neben der endoskopischen Biopsie diagnostisches Mittel der Wahl. Eine Heilung ist bei allen Tumorarten nur durch eine radikal chirurgische Resektion im Gesunden möglich. Durch eine Zunahme der Radikalität konnte in den letzten Jahren eine deutliche Verbesserung der 5-Jahres-Überlebensraten erreicht werden. Ein klinischer Benefit für adjuvante bzw. neoadjuvante Therapiemaßnahmen konnte dagegen bisher nicht nachgewiesen werden. In der Palliation sind die endoskopische Drainage der Gallenwege und die photodynamische Therapie fest etabliert. Radio- und Chemotherapie sind nur im Rahmen von Studien sinnvoll. Neuere Therapieansätze sind die Brachytherapie, moderne Chemotherapeutika sowie die COX-2- und Tyrosinkinaserezeptorinhibition.

Abstract

Carcinoma of the biliary tree are rare tumours of the gastrointestinal tract with a rising incidence during the last years. Biliary neoplasms are classified into intra- and extrahepatic cholangiocarcinoma (Klatskin tumour, middle and distal extrahepatic tumours), gallbladder cancer, and ampullary carcinoma. Transformation of normal into malignant bile duct tissue requires a chain of consecutive gene mutations, similar to the adenoma-dysplasia-carcinoma-sequence in colon cancer. Abdominal ultrasound, combined non-invasive magnetic resonance cholangiography/tomography (MRC/MRT), and facultatively endoscopic retrograde cholangiography (ERC) for unclear diagnosis, represent the gold standard for primary diagnosis. For ampullary carcinoma, endosonography and endoscopic biopsy are the diagnostic tools of choice. Cure is attainable only by formal curative radical surgical resection. Increasing surgical radicality within the last years enabled clearly improved 5-year survival rates. In contrast, there has been no clinical benefit for adjuvant and neoadjuvant therapies. For palliation, bile duct stenting and photodynamic therapy are established methods. Radio- and chemotherapy should be reserved for clinical studies. New therapeutic approaches include brachytherapy, the use of modern chemotherapeutics, COX-2- and tyrosine kinase-receptor-inhibitors.

Intrahepatisches Gallengangskarzinom - hiläres Gallengangskarzinom - Gallenblasenkarzinom - Ampulla-Vateri-Karzinom - Diagnostik - Therapie

Intrahepatic cholangiocarcinoma - hilar cholangiocarcinoma - gallbladder cancer - ampulla-Vateri carcinoma - diagnosis - therapy

Literatur

• 1 de Groen P C, Gores G J, LaRusso N F. et al . Biliary tract cancers.  N Engl J Med. 1999;  341 1368-1378
• 2 Taylor-Robinson S D, Toledano M B, Arora S. et al . Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968 - 1998.  Gut. 2001;  48 816-820
• 3 Jean M, Dua K. Tumors of the ampulla of Vater.  Curr Gastroenterol Rep. 2003;  5 171-175
• 4 Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States.  Hepatology. 2001;  33 1353-1357
• 5 Khan S A, Taylor-Robinson S D, Toledano M B. et al . Changing international trends in mortality rates for liver, biliary and pancreatic tumours.  J Hepatol. 2002;  37 806-813
• 6 Davila J A, El-Serag H B. Cholangiocarcinoma: the „other” liver cancer on the rise.  Am J Gastroenterol. 2002;  97 3199-3200
• 7 Redaelli C A, Buchler M W, Schilling M K. et al . High coincidence of Mirizzi syndrome and gallbladder carcinoma.  Surgery. 1997;  121 58-63
• 8 Chow W H, Johansen C, Gridley G. et al . Gallstones, cholecystectomy and risk of cancers of the liver, biliary tract and pancreas.  Br J Cancer. 1999;  79 640-644
• 9 Okamoto M, Okamoto H, Kitahara F. et al . Ultrasonographic evidence of association of polyps and stones with gallbladder cancer.  Am J Gastroenterol. 1999;  94 446-450
• 10 Aldridge M C, Bismuth H. Gallbladder cancer: the polyp-cancer sequence.  Br J Surg. 1990;  77 363-364
• 11 Chapman R W. Risk factors for biliary tract carcinogenesis.  Ann Oncol. 1999;  10 (Suppl 4) 308-311
• 12 Tocchi A, Mazzoni G, Liotta G. et al . Late development of bile duct cancer in patients who had biliary-enteric drainage for benign disease: a follow-up study of more than 1,000 patients.  Ann Surg. 2001;  234 210-214
• 13 Bettschart V, Clayton R A, Parks R W. et al . Cholangiocarcinoma arising after biliary-enteric drainage procedures for benign disease.  Gut. 2002;  51 128-129
• 14 Tomimatsu M, Ishiguro N, Taniai M. et al . Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular-cholangiocarcinoma) in Japan.  Cancer. 1993;  72 683-688
• 15 Pauli R M, Pauli M E, Hall J G. Gardner syndrome and periampullary malignancy.  Am J Med Genet. 1980;  6 205-219
• 16 Gouma D J, Obertop H, Vismans J. et al . Progression of a benign epithelial ampullary tumor to adenocarcinoma.  Surgery. 1987;  101 501-504
• 17 Lazcano-Ponce E C, Miquel J F, Munoz N. et al . Epidemiology and molecular pathology of gallbladder cancer.  CA Cancer J Clin. 2001;  51 349-364
• 18 Misra S, Chaturvedi A, Goel M M. et al . Overexpression of p53 protein in gallbladder carcinoma in North India.  Eur J Surg Oncol. 2000;  26 164-167
• 19 Ahrendt S A, Rashid A, Chow J T. et al . p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer.  J Hepatobiliary Pancreat Surg. 2000;  7 426-431
• 20 Chow N H, Huang S M, Chan S H. et al . Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract.  Anticancer Res. 1995;  15 1055-1059
• 21 Furubo S, Harada K, Shimonishi T. et al . Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma.  Histopathology. 1999;  35 230-240
• 22 Radaeva S, Ferreira-Gonzalez A, Sirica A E. Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: A link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma.  Hepatology. 1999;  29 1453-1462
• 23 Sturm P D, Baas I O, Clement M J. et al . Alterations of the p53 tumor-suppressor gene and K-ras oncogene in perihilar cholangiocarcinomas from a high-incidence area.  Int J Cancer. 1998;  78 695-698
• 24 Bergquist A, Glaumann H, Stal P. et al . Biliary dysplasia, cell proliferation and nuclear DNA-fragmentation in primary sclerosing cholangitis with and without cholangiocarcinoma.  J Intern Med. 2001;  249 69-75
• 25 Della T orre G, Pasquini G, Pilotti S. et al . TP53 mutations and mdm2 protein overexpression in cholangiocarcinomas.  Diagn Mol Pathol. 2000;  9 41-46
• 26 Fiorentino M, D’Errico A, Altimari A. et al . High levels of BCL-2 messenger RNA detected by in situ hybridization in human hepatocellular and cholangiocellular carcinomas.  Diagn Mol Pathol. 1999;  8 189-194
• 27 Harnois D M, Que F G, Celli A. et al . Bcl-2 is overexpressed and alters the threshold for apoptosis in a cholangiocarcinoma cell line.  Hepatology. 1997;  26 884-890
• 28 Tannapfel A, Weinans L, Geissler F. et al . Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver.  Dig Dis Sci. 2000;  45 317-324
• 29 Tullo A, D’Erchia A M, Honda K. et al . New p53 mutations in hilar cholangiocarcinoma.  Eur J Clin Invest. 2000;  30 798-803
• 30 Caca K, Feisthammel J, Klee K. et al . Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines.  Int J Cancer. 2002;  97 481-488
• 31 Ahrendt S A, Eisenberger C F, Yip L. et al . Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma.  J Surg Res. 1999;  84 88-93
• 32 Horie S, Endo K, Kawasaki H. et al . Overexpression of MDM2 protein in intrahepatic cholangiocarcinoma: relationship with p53 overexpression, Ki-67 labeling, and clinicopathological features.  Virchows Arch. 2000;  437 25-30
• 33 Tannapfel A, Benicke M, Katalinic A. et al . Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver.  Gut. 2000;  47 721-727
• 34 Ito Y, Takeda T, Sasaki Y. et al . Expression of Fas and Fas ligand reflects the biological characteristics but not the status of apoptosis of intrahepatic cholangiocellular carcinoma.  Int J Mol Med. 2000;  6 581-586
• 35 Que F G, Phan V A, Phan V H. et al . Cholangiocarcinomas express Fas ligand and disable the Fas receptor.  Hepatology. 1999;  30 1398-1404
• 36 Shimonishi T, Isse K, Shibata F. et al . Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance.  Hepatology. 2000;  32 761-769
• 37 Yoon J H, Werneburg N W, Higuchi H. et al . Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism.  Cancer Res. 2002;  62 6500-6505
• 38 Chariyalertsak S, Sirikulchayanonta V, Mayer D. et al . Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma.  Gut. 2001;  48 80-86
• 39 Sirica A E, Lai G H, Zhang Z. Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potenzial therapeutic strategies.  J Gastroenterol Hepatol. 2001;  16 363-372
• 40 Yoon J H, Higuchi H, Werneburg N W. et al . Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line.  Gastroenterology. 2002;  122 985-993
• 41 Caplin M, Khan K, Savage K. et al . Expression and processing of gastrin in hepatocellular carcinoma, fibrolamellar carcinoma and cholangiocarcinoma.  J Hepatol. 1999;  30 519-526
• 42 Ito Y, Miyoshi E, Takeda T. et al . ets-1 expression in extrahepatic bile duct carcinoma and cholangiocellular carcinoma.  Oncology. 2000;  58 248-252
• 43 Harada K, Zen Y, Kanemori Y. et al . Human REG I gene is up-regulated in intrahepatic cholangiocarcinoma and its precursor lesions.  Hepatology. 2001;  33 1036-1042
• 44 Lavaissiere L, Jia S, Nishiyama M. et al . Overexpression of human aspartyl(asparaginyl)beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma.  J Clin Invest. 1996;  98 1313-1323
• 45 Terada T, Ueyama J, Ukita Y. et al . Protein expression of double-stranded RNA-activated protein kinase (PKR) in intrahepatic bile ducts in normal adult livers, fetal livers, primary biliary cirrhosis, hepatolithiasis and intrahepatic cholangiocarcinoma.  Liver. 2000;  20 450-457
• 46 Itoi T, Shinohara Y, Takeda K. et al . Detection of telomerase activity in biopsy specimens for diagnosis of biliary tract cancers.  Gastrointest Endosc. 2000;  52 380-386
• 47 Endo K, Ashida K, Miyake N. et al . E-cadherin gene mutations in human intrahepatic cholangiocarcinoma.  J Pathol. 2001;  193 310-317
• 48 Rashid A, Gao Y T, Bhakta S. et al . Beta-catenin mutations in biliary tract cancers: a population-based study in China.  Cancer Res. 2001;  61 3406-3409
• 49 Kang Y K, Kim W H, Lee H W. et al . Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma.  Lab Invest. 1999;  79 477-483
• 50 Kawahara N, Ono M, Taguchi K. et al . Enhanced expression of thrombospondin-1 and hypovascularity in human cholangiocarcinoma.  Hepatology. 1998;  28 1512-1517
• 51 Jaiswal M, LaRusso N F, Burgart L J. et al . Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism.  Cancer Res. 2000;  60 184-190
• 52 Jaiswal M, LaRusso N F, Gores G J. Nitric oxide in gastrointestinal epithelial cell carcinogenesis: linking inflammation to oncogenesis.  Am J Physiol Gastrointest Liver Physiol. 2001;  281 G626-G634
• 53 Torok N J, Higuchi H, Bronk S. et al . Nitric oxide inhibits apoptosis downstream of cytochrome C release by nitrosylating caspase 9.  Cancer Res. 2002;  62 1648-1653
• 54 Ramage J K, Donaghy A, Farrant J M. et al . Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis.  Gastroenterology. 1995;  108 865-869
• 55 Patel A H, Harnois D M, Klee G G. et al . The utility of CA 19 - 9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis.  Am J Gastroenterol. 2000;  95 204-207
• 56 Hultcrantz R, Olsson R, Danielsson A. et al . A 3-year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis.  J Hepatol. 1999;  30 669-673
• 57 Nichols J C, Gores G J, LaRusso N F. et al . Diagnostic role of serum CA 19 - 9 for cholangiocarcinoma in patients with primary sclerosing cholangitis.  Mayo Clin Proc. 1993;  68 874-879
• 58 Chalasani N, Baluyut A, Ismail A. et al . Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study.  Hepatology. 2000;  31 7-11
• 59 Hann L E, Schwartz L H, Panicek D M. et al . Tumor involvement in hepatic veins: comparison of MR imaging and US for preoperative assessment.  Radiology. 1998;  206 651-656
• 60 Fulcher A S, Turner M A. MR cholangiopancreatography.  Radiol Clin North Am. 2002;  40 1363-1376
• 61 Yeh T S, Jan Y Y, Tseng J H. et al . Malignant perihilar biliary obstruction: magnetic resonance cholangiopancreatographic findings.  Am J Gastroenterol. 2000;  95 432-440
• 62 Zidi S H, Prat F, Le G uen O. et al . Performance characteristics of magnetic resonance cholangiography in the staging of malignant hilar strictures.  Gut. 2000;  46 103-106
• 63 Manfredi R, Brizi M G, Masselli G. et al . Malignant biliary hilar stenosis: MR cholangiography compared with direct cholangiography.  Radiol Med (Torino). 2001;  102 48-54
• 64 Lopera J E, Soto J A, Munera F. Malignant hilar and perihilar biliary obstruction: use of MR cholangiography to define the extent of biliary ductal involvement and plan percutaneous interventions.  Radiology. 2001;  220 90-96
• 65 Adamek H E, Albert J, Weitz M. et al . A prospective evaluation of magnetic resonance cholangiopancreatography in patients with suspected bile duct obstruction.  Gut. 1998;  43 680-683
• 66 Angulo P, Pearce D H, Johnson C D. et al . Magnetic resonance cholangiography in patients with biliary disease: its role in primary sclerosing cholangitis.  J Hepatol. 2000;  33 520-527
• 67 Nesbit G M, Johnson C D, James E M. et al . Cholangiocarcinoma: diagnosis and evaluation of resectability by CT and sonography as procedures complementary to cholangiography.  AJR Am J Roentgenol. 1988;  151 933-938
• 68 Cannon M E, Carpenter S L, Elta G H. et al . EUS compared with CT, magnetic resonance imaging, and angiography and the influence of biliary stenting on staging accuracy of ampullary neoplasms.  Gastrointest Endosc. 1999;  50 27-33
• 69 Kubo H, Chijiiwa Y, Akahoshi K. et al . Pre-operative staging of ampullary tumours by endoscopic ultrasound.  Br J Radiol. 1999;  72 443-447
• 70 Khan S A, Davidson B R, Goldin R. et al . Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document.  Gut. 2002;  51 (Suppl 6) VI1-9
• 71 Rumalla A, Baron T H, Leontovich O. et al . Improved diagnostic yield of endoscopic biliary brush cytology by digital image analysis.  Mayo Clin Proc. 2001;  76 29-33
• 72 Klump B, Hsieh C J, Dette S. et al . Promoter methylation of INK4a/ARF as detected in bile-significance for the differential diagnosis in biliary disease.  Clin Cancer Res. 2003;  9 1773-1778
• 73 Yamaguchi K, Enjoji M, Kitamura K. Endoscopic biopsy has limited accuracy in diagnosis of ampullary tumors.  Gastrointest Endosc. 1990;  36 588-592
• 74 Ponchon T, Berger F, Chavaillon A. et al . Contribution of endoscopy to diagnosis and treatment of tumors of the ampulla of Vater.  Cancer. 1989;  64 161-167
• 75 Kluge R, Schmidt F, Caca K. et al . Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer.  Hepatology. 2001;  33 1029-1035
• 76 Keiding S, Hansen S B, Rasmussen H H. et al . Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography.  Hepatology. 1998;  28 700-706
• 77 Fujita N, Noda Y, Kobayashi G. et al . Staging of bile duct carcinoma by EUS and IDUS.  Endoscopy. 1998;  30 (Suppl 1) A132-A134
• 78 Jarnagin W R, Fong Y, DeMatteo R P. et al . Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma.  Ann Surg. 2001;  234 507-517, discussion 517 - 519
• 79 Sobin L H, Wittekind C. (eds) .UICC: TNM Classification of Malignant Tumors. 6th ed. Wiley-Liss New York; 2002: 74-85
• 80 Bismuth H, Nakache R, Diamond T. Management strategies in resection for hilar cholangiocarcinoma.  Ann Surg. 1992;  215 31-38
• 81 Casavilla F A, Marsh J W, Iwatsuki S. et al . Hepatic resection and transplantation for peripheral cholangiocarcinoma.  J Am Coll Surg. 1997;  185 429-436
• 82 Busuttil R W, Farmer D G. The surgical treatment of primary hepatobiliary malignancy.  Liver Transpl Surg. 1996;  2 114-130
• 83 Nakeeb A, Pitt H A, Sohn T A. et al . Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.  Ann Surg. 1996;  224: 463 - 473, discussion 473 - 475
• 84 Wall W J. Liver transplantation for hepatic and biliary malignancy.  Semin Liver Dis. 2000;  20 425-436
• 85 Meyer C G, Penn I, James L. Liver transplantation for cholangiocarcinoma: results in 207 patients.  Transplantation. 2000;  69 1633-1637
• 86 Birkmeyer J D, Siewers A E, Finlayson E V. et al . Hospital volume and surgical mortality in the United States.  N Engl J Med. 2002;  346 1128-1137
• 87 Birkmeyer J D, Stukel T A, Siewers A E. et al . Surgeon volume and operative mortality in the United States.  N Engl J Med. 2003;  349 2117-2127
• 88 Madoff D C, Hicks M E, Abdalla E K. et al . Portal vein embolization with polyvinyl alcohol particles and coils in preparation for major liver resection for hepatobiliary malignancy: safety and effectiveness - study in 26 patients.  Radiology. 2003;  227 251-260
• 89 Abdalla E K, Hicks M E, Vauthey J N. Portal vein embolization: rationale, technique and future prospects.  Br J Surg. 2001;  88 165-175
• 90 Sewnath M E, Karsten T M, Prins M H. et al . A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice.  Ann Surg. 2002;  236 17-27
• 91 Kawasaki S, Imamura H, Kobayashi A. et al . Results of surgical resection for patients with hilar bile duct cancer: application of extended hepatectomy after biliary drainage and hemihepatic portal vein embolization.  Ann Surg. 2003;  238 84-92
• 92 Pichlmayr R, Weimann A, Klempnauer J. et al . Surgical treatment in proximal bile duct cancer. A single-center experience.  Ann Surg 1996. 224 628-638
• 93 Neuhaus P, Jonas S, Bechstein W O. et al . Extended resections for hilar cholangiocarcinoma.  Ann Surg. 1999;  230 808-818, discussion 819
• 94 Hadjis N S, Blenkharn J I, Alexander N. et al . Outcome of radical surgery in hilar cholangiocarcinoma.  Surgery. 1990;  107 597-604
• 95 Seyama Y, Kubota K, Sano K. et al . Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate.  Ann Surg. 2003;  238 73-83
• 96 Gerhards M F, van Gulik T M, de Wit L T. et al . Evaluation of morbidity and mortality after resection for hilar cholangiocarcinoma - a single center experience.  Surgery. 2000;  127 395-404
• 97 Huang Z Q, Zhou N X, Wang D D. et al . Changing trends of surgical treatment of hilar bile duct cancer: clinical and experimental perspectives.  World J Gastroenterol. 2000;  6 777-782
• 98 Madariaga J R, Iwatsuki S, Todo S. et al . Liver resection for hilar and peripheral cholangiocarcinomas: a study of 62 cases.  Ann Surg. 1998;  227 70-79
• 99 Iwatsuki S, Todo S, Marsh J W. et al . Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation.  J Am Coll Surg. 1998;  187 358-364
• 100 Tashiro S, Tsuji T, Kanemitsu K. et al . Prolongation of survival for carcinoma at the hepatic duct confluence.  Surgery. 1993;  113 270-278
• 101 Pitt H A, Nakeeb A, Abrams R A. et al . Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival.  Ann Surg. 1995;  221: 788 - 797, discussion 797 - 798
• 102 Hejna M, Pruckmayer M, Raderer M. The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature.  Eur J Cancer. 1998;  34 977-986
• 103 Wiedmann M, Caca K, Berr F. et al . Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase II pilot study.  Cancer. 2003;  97 2783-2790
• 104 Gores G J. Cholangiocarcinoma: current concepts and insights.  Hepatology. 2003;  37 961-969
• 105 Posner S, Colletti L, Knol J. et al . Safety and long-term efficacy of transduodenal excision for tumors of the ampulla of Vater.  Surgery. 2000;  128 694-701
• 106 Witzigmann H, Mobius C, Uhlmann D. et al . Behandlungskonzept von Adenomen der Papilla Vateri.  Chirurg. 2000;  71 196-201
• 107 Catalano M F, Linder J D, Chak A. et al . Endoscopic management of adenoma of the major duodenal papilla.  Gastrointest Endosc. 2004;  59 225-232
• 108 Norton I D, Gostout C J, Baron T H. et al . Safety and outcome of endoscopic snare excision of the major duodenal papilla.  Gastrointest Endosc. 2002;  56 239-243
• 109 Bertoni G, Sassatelli R, Nigrisoli E. et al . Endoscopic snare papillectomy in patients with familial adenomatous polyposis and ampullary adenoma.  Endoscopy. 1997;  29 685-688
• 110 Binmoeller K F, Boaventura S, Ramsperger K. et al . Endoscopic snare excision of benign adenomas of the papilla of Vater.  Gastrointest Endosc. 1993;  39 127-131
• 111 Neoptolemos J P, Talbot I C, Carr-Locke D L. et al . Treatment and outcome in 52 consecutive cases of ampullary carcinoma.  Br J Surg. 1987;  74 957-961
• 112 Yamaguchi K, Chijiiwa K, Saiki S. et al . Retrospective analysis of 70 operations for gallbladder carcinoma.  Br J Surg. 1997;  84 200-204
• 113 Gerhardt T, Mey U, Sauerbruch T. et al . Palliative Therapie des inoperablen Gallengangskarzinoms.  Dtsch Med Wochenschr. 2002;  127 1835-1839
• 114 Nordback I H, Pitt H A, Coleman J. et al . Unresectable hilar cholangiocarcinoma: percutaneous versus operative palliation.  Surgery. 1994;  115 597-603
• 115 Smith A C, Dowsett J F, Russell R C. et al . Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction.  Lancet. 1994;  344 1655-1660
• 116 Speer A G, Cotton P B, Russell R C. et al . Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice.  Lancet. 1987;  2 57-62
• 117 Doctor N, Dick R, Rai R. et al . Results of percutaneous plastic stents for malignant distal biliary obstruction following failed endoscopic stent insertion and comparison with current literature on expandable metallic stents.  Eur J Gastroenterol Hepatol. 1999;  11 775-780
• 118 Lammer J, Neumayer K. Biliary drainage endoprostheses: experience with 201 placements.  Radiology. 1986;  159 625-629
• 119 Mueller P R, Ferrucci J T Jr, Teplick S K. et al . Biliary stent endoprosthesis: analysis of complications in 113 patients.  Radiology. 1985;  156 637-639
• 120 Halm U, Schiefke I, Fleig W E. et al . Ofloxacin and ursodeoxycholic acid versus ursodeoxycholic acid alone to prevent occlusion of biliary stents: a prospective, randomized trial.  Endoscopy. 2001;  33 491-494
• 121 Barrioz T, Ingrand P, Besson I. et al . Randomised trial of prevention of biliary stent occlusion by ursodeoxycholic acid plus norfloxacin.  Lancet. 1994;  344 581-582
• 122 Ghosh S, Palmer K R. Prevention of biliary stent occlusion using cyclical antibiotics and ursodeoxycholic acid.  Gut. 1994;  35 1757-1759
• 123 Lammer J, Stoffler G, Petek W W. et al . In vitro long-term perfusion of different materials for biliary endoprostheses.  Invest Radiol. 1986;  21 329-331
• 124 Lammer J, Hausegger K A, Fluckiger F. et al . Common bile duct obstruction due to malignancy: treatment with plastic versus metal stents.  Radiology. 1996;  201 167-172
• 125 Prat F, Chapat O, Ducot B. et al . A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct.  Gastrointest Endosc. 1998;  47 1-7
• 126 Knyrim K, Wagner H J, Pausch J. et al . A prospective, randomized, controlled trial of metal stents for malignant obstruction of the common bile duct.  Endoscopy. 1993;  25 207-212
• 127 Wagner H J, Knyrim K, Vakil N. et al . Plastic endoprostheses versus metal stents in the palliative treatment of malignant hilar biliary obstruction. A prospective and randomized trial.  Endoscopy 1993. 25 213-218
• 128 Tham T C, Carr-Locke D L, Vandervoort J. et al . Management of occluded biliary Wallstents.  Gut. 1998;  42 703-707
• 129 Deviere J, Baize M, de Toeuf J. et al . Long-term follow-up of patients with hilar malignant stricture treated by endoscopic internal biliary drainage.  Gastrointest Endosc. 1988;  34 95-101
• 130 Polydorou A A, Cairns S R, Dowsett J F. et al . Palliation of proximal malignant biliary obstruction by endoscopic endoprosthesis insertion.  Gut. 1991;  32 685-689
• 131 De Palma G D, Galloro G, Siciliano S. et al . Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study.  Gastrointest Endosc. 2001;  53 547-553
• 132 De Palma G D, Pezzullo A, Rega M. et al . Unilateral placement of metallic stents for malignant hilar obstruction: A prospective study.  Gastrointest Endosc. 2003;  58 50-53
• 133 Ortner M A, Liebetruth J, Schreiber S. et al . Photodynamic therapy of nonresectable cholangiocarcinoma.  Gastroenterology. 1998;  114 536-542
• 134 Berr F, Wiedmann M, Tannapfel A. et al . Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival.  Hepatology. 2000;  31 291-298
• 135 Ortner M EJ, Caca K, Berr F. et al . Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study.  Gastroenterology. 2003;  125 1355-1363
• 136 Dumoulin F L, Gerhardt T, Fuchs S. et al . Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma.  Gastrointest Endosc. 2003;  57 860-867
• 137 Bowling T E, Galbraith S M, Hatfield A R. et al . A retrospective comparison of endoscopic stenting alone with stenting and radiotherapy in non-resectable cholangiocarcinoma.  Gut. 1996;  39 852-855
• 138 Kamada T, Saitou H, Takamura A. et al . The role of radiotherapy in the management of extrahepatic bile duct cancer: an analysis of 145 consecutive patients treated with intraluminal and/or external beam radiotherapy.  Int J Radiat Oncol Biol Phys. 1996;  34 767-774
• 139 Mittal B, Deutsch M, Iwatsuki S. Primary cancers of extrahepatic biliary passages.  Int J Radiat Oncol Biol Phys. 1985;  11 849-854
• 140 Eschelman D J, Shapiro M J, Bonn J. et al . Malignant biliary duct obstruction: long-term experience with Gianturco stents and combined-modality radiation therapy.  Radiology. 1996;  200 717-724
• 141 Rumalla A, Baron T H. Evaluation and endoscopic palliation of cholangiocarcinoma. Management of cholangiocarcinoma.  Dig Dis. 1999;  17 194-200
• 142 Glimelius B, Hoffman K, Sjoden P O. et al . Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer.  Ann Oncol. 1996;  7 593-600
• 143 Schiefke I, Zabel-Langhennig A, Wiedmann M. et al . Self-expandable metallic stents for malignant duodenal obstruction caused by biliary tract cancer.  Gastrointest Endosc. 2003;  58 213-219
• 144 Chaudhary A, Dhar P, Tomey S. et al . Segment III cholangiojejunostomy for carcinoma of the gallbladder.  World J Surg. 1997;  21 866-870, discussion 870 - 871
• 145 Kapoor V K, Pradeep R, Haribhakti S P. et al . Intrahepatic segment III cholangiojejunostomy in advanced carcinoma of the gallbladder.  Br J Surg. 1996;  83 1709-1711
• 146 Patt Y Z, Jones D V Jr, Hoque A. et al . Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2 b for biliary tract cancer.  J Clin Oncol. 1996;  14 2311-2315
• 147 Castro M P. Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: a case report.  Cancer. 1998;  82 639-641
• 148 Harvey J H, Smith F P, Schein P S. 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract.  J Clin Oncol. 1984;  2 1245-1248
• 149 Gupta R A, Dubois R N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.  Nat Rev Cancer. 2001;  1 11-21
• 150 Steinbach G, Lynch P M, Phillips R K. et al . The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.  N Engl J Med. 2000;  342 1946-1952
• 151 Wiedmann M, Kreth F, Feisthammel J. et al . Imatinib mesylate (STI571; Glivec) - a new approach in the treatment of biliary tract cancer?.  Anticancer Drugs. 2003;  14 751-760
• 152 Feisthammel J, Wiedmann M, Kreth F. et al . EGFR Expression und der Effekt von Gefitinib auf das in-vitro Wachstum von Tumoren der Gallenwege.  Z Gastroenterol. 2004;  42 77A
• 153 Date K, Matsumoto K, Kuba K. et al . Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor.  Oncogene. 1998;  17 3045-3054